Ribosome hopping and translational frameshifting are inadequate alternatives to translational attenuation in cat-86 regulation


     Related Videos
Ribosome Ratchet
  • Ribosome Ratchet

  • The ratchet-like rearrangements at the interface between two ribosomal subunits may help move the mR...

Biology Chromosome Cell Cytoplasm Ribosome Lysosome Golgi Mitochondria Nucleus DNA Gene Mo...

     Related Hubpages

    •  Doc. Url:    Embed Code: 

    • PubMed  status
      (0) (0 Votes)
      Views: (1036)   Date: (20-01-09)   Pages: ()
    • Author:  Rogers EJ  Ambulos NP Jr  Lovett PS.  

    • Abstract:  Ribosome hopping and translational frameshifting are inadequate alternatives to translational attenuation in cat-86 regulation. Rogers EJ, Ambulos NP Jr, Lovett PS. Department of Biological Sciences, University of Maryland Baltimore County, Catonsville 21228. The induction of cat-86 by chloramphenicol has been proposed to follow the translational attenuation model. In the absence of inducer, the cat-86 gene is transcribed but remains phenotypically unexpressed because the transcripts sequester the ribosome binding site for the cat coding sequence in a stable stem-loop structure, preventing translation initiation. The translational attenuation model proposes that the natural inducer, chloramphenicol, stalls a ribosome in the leader region of cat transcripts, which causes localized melting of the downstream stem-loop structure, allowing initiation of translation of the cat-86 coding sequence. Although it is established that ribosome stalling in the cat-86 leader can induce translation of the coding sequence, several subsequent steps predicted by the model remain to be experimentally confirmed. As a consequence, the present evidence for cat-86 regulation can also be explained by two other potential control devices, ribosome hopping and translational frameshifting. Here we describe experiments designed to determine whether the alternatives to translational attenuation regulate cat-86. The results obtained are inconsistent with both competing models and are consistent with predictions made by the translational attenuation model. PMID: 1720771 [PubMed - indexed for MEDLINE] PMCID: PMC212580

         Related Documents

           Related Groups

             Related Science News

               More on Sciencestage

               Answers

               News
          • Watching the engine of life, in real time, to understand how things go wrong
            (PhysOrg.com) -- Ruben Gonzalez views ribosomes—the minute particles in cells that make proteins—as the “machines” of life. Naturally, the associate professor of chemistry is interested in watching these little protein-producing factories in real time, especially when they malfunction and cause disease.
          • Rib-X Pharmaceuticals Receives $3 Million Milestone Payment from Sanofi in the RX-04 Collaboration
            Rib-X Pharmaceuticals, Inc. announced today the receipt of a $3 million milestone payment from Sanofi . The payment is the fourth received for milestones achieved following the signing in July 2011 of a worldwide research collaboration and option for license with Sanofi for novel classes of antibiotics resulting from Rib-X’s RX-04 program for the treatment of drug resistant Gram-negative and ...
          • Video Games Lead to New Paths to Treat Cancer, Other Diseases
            Samuel Cho, a researcher at Wake Forest University, uses graphics processing units (GPUs), the technology that makes video game images so realistic, to simulate the inner workings of human cells. His research points to new paths for tumor-killing drugs to treat cancer and other diseases.
          • Alnylam to Sell $80.6M in Stock
            Alnylam Pharmaceuticals this week announced that it would offer for public sale 7.5 million of its shares at $10.75 per share.
          • People in the News: Tony Sedgwick, Thomas Christely
            Sedgwick joined Silence last September. Before that, he was CEO of Novacta , Daniolabs , and Cambridge Biotechnology .
          • People in the News: Charlie Rodi, Steven Hyman
            Molecular diagnostic company Trovagene has appointed Charlie Rodi to vice president and chief technology officer. Previous positions include director of the Monsanto Genome Sequencing Center and executive vice president of genomics at Sequenom . He has also held positions at G.D. Searle , where he helped use nucleic acid biomarkers in drug development, and at ICx BioSystems , where he helped ...
          • Prions point to a new style of evolution
            A form of evolution that involves neither genetic nor epigenetic changes to the DNA has been seen in yeast
          • Looks Like We’re Still Looking for Earthly Life Forms on Other Planets
            In late 2010, NASA set the Internet buzzing when it called a press conference to discuss an astrobiological finding that would impact the search for extraterrestrial life. Many speculated that some primitive life had been found on Mars or one of Saturn’s moons. But the evidence was found on Earth; a strain of bacteria in [...]
          • Proteomics - Technologies, Markets and Companies
            NEW YORK, Feb. 1, 2012  /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Proteomics - Technologies, Markets and Companies http://www.reportlinker.com/p0203550/Proteomics---Technologies-Markets-and-Companies.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=GenomicsThis ...
          • FASEB SRC announces conference registration open for: Nucleic Acid Enzymes
            ( Federation of American Societies for Experimental Biology ) The Federation of American Societies for Experimental Biology announces the opening of registration for the Science Research Conference: Nucleic Acid Enzymes.

               Related on Wikipedia




























           

          Powered free by PHPmotion